Artelo Biosciences (ARTL) CEO awarded 154,713 stock options

Rhea-AI Filing Summary

Artelo Biosciences reported a Form 4 insider transaction for President, CEO, CFO, Treasurer and Secretary Gregory D. Gorgas. He was granted 154,713 stock options on January 29, 2026 with an exercise price of $1.68 per share and expiration on January 29, 2036.

These options vest in equal monthly installments, with 1/48 of the shares vesting each month starting from a vesting commencement date of January 1, 2026, so long as he continues as a service provider. The entire grant is scheduled to be fully vested after four years.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gorgas Gregory D.

Role Pres, CEO, CFO, Treas & Secr

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	154,713	$0.00	--

Holdings After Transaction: Stock Options (right to buy) — 154,713 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gorgas Gregory D.

(Last) (First) (Middle)

C/O ARTELO BIOSCIENCES, INC.

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres, CEO, CFO, Treas & Secr

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.68	01/29/2026		A		154,713		(1)	01/29/2036	Common Stock	154,713	$0.00	154,713	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date, such that the option shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 1, 2026.

Remarks:

	/s/ Gregory D. Gorgas	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Artelo Biosciences (ARTL) report on this Form 4?

Artelo Biosciences reported a grant of stock options to Gregory D. Gorgas. He received 154,713 options on January 29, 2026, as equity compensation in his roles as President, CEO, CFO, Treasurer and Secretary of the company.

How many stock options were granted to Gregory D. Gorgas at ARTL?

Gregory D. Gorgas was granted 154,713 stock options. All 154,713 derivative securities are shown as beneficially owned directly following the transaction, reflecting the full size of this equity award documented in the Form 4 filing.

What are the vesting terms for Gregory Gorgas’s Artelo Biosciences options?

The options vest in 48 equal monthly installments, with one forty-eighth of the shares vesting each month. Vesting begins from the January 1, 2026 vesting commencement date, and full vesting occurs on the four-year anniversary, subject to continued service.

What is the exercise price and expiration date of the ARTL stock options?

The stock options have an exercise price of $1.68 per share. They are scheduled to expire on January 29, 2036, giving Gregory D. Gorgas a long time window in which he can choose to exercise them if vested.

Is this Artelo Biosciences Form 4 a grant or a sale of securities?

The Form 4 reflects a grant of derivative securities, not a sale. The transaction code is “A” for acquisition, covering stock options (right to buy) awarded to Gregory D. Gorgas as compensation rather than an open-market purchase or sale.

How is ownership of the granted ARTL options reported for Gregory D. Gorgas?

Ownership of the 154,713 stock options is reported as direct. The Form 4 lists the ownership form as “D” for direct, with no indication of indirect holding through another entity in the nature of ownership field or the accompanying footnote.